澳大利亚高危吸烟者低剂量CT肺癌筛查的成本效果评估
本研究将澳大利亚成本与生存数据应用于美国NLST试验观察到的结局,评估高危吸烟者LDCT肺癌筛查的成本效果。结果显示每获得生命年增量成本为138,000澳元,每获得质量调整生命年增量成本为233,000澳元,远高于澳大利亚30,000至50,000澳元/QALY的意愿支付阈值。结论认为采用NLST选择与实施标准的LDCT筛查在澳大利亚不太可能具有成本效果。
要点
- LDCT筛查ICER为233,000澳元/QALY,远超澳大利亚30,000至50,000澳元/QALY的阈值。
- 考虑全因死亡率影响时ICER为157,000澳元/QALY,仍高于意愿支付阈值。
- 未来评估应考虑替代筛查标准、间隔、结节管理及新疗法影响。
核心结论
- 采用NLST选择与实施标准的LDCT肺癌筛查在澳大利亚不太可能具有成本效果。
研究设计与样本
- 将澳大利亚成本与生存数据应用于美国NLST试验观察到的结局,进行成本效果分析。
- NLST中55至74岁高危吸烟者每年筛查三轮,肺癌死亡率获益20%。
- 成本数据来自2015年Medicare Benefits Schedule、2012年澳大利亚医院研究、新南威尔士州癌症登记处(2005-2009)及澳大利亚生命表。
- 计算10年时间 horizon 的增量成本效果比(ICER)。
主要发现
- LDCT筛查的ICER为每获得生命年138,000澳元(80%CI:84,700-353,000)。
- 每获得质量调整生命年(QALY)的ICER为233,000澳元(80%CI:128,000-1,110,000)。
- 考虑全因死亡率影响时ICER为157,000澳元/QALY。
关键数值与推荐
- 澳大利亚意愿支付阈值为30,000至50,000澳元/QALY。
- LDCT筛查ICER为233,000澳元/QALY,高于上述阈值。
- 考虑全因死亡率时ICER为157,000澳元/QALY,仍高于阈值。
临床怎么用
- 在澳大利亚采用NLST标准进行LDCT肺癌筛查可能不具有成本效果。
- 决策时应考虑替代筛查 eligibility 标准、间隔及结节管理策略。
局限性
- 成本效果评估基于NLST的筛查参与率、肺癌率及健康效用结局。
- 未充分考虑新疗法影响、偶然发现检查成本及戒烟干预的整合。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Health economic evaluations of lung cancer screening with low-dose computed tomography (LDCT) that are underpinned by clinical outcomes are relatively few. METHODS: We assessed the cost-effectiveness of LDCT lung screening in Australia by applying Australian cost and survival data to the outcomes observed in the U.S. National Lung Screening Trial (NLST), in which a 20% lung cancer mortality benefit was demonstrated for three rounds of annual screening among high-risk smokers age 55 to 74 years. Screening-related costs were estimated from Medicare Benefits Schedule reimbursement rates (2015), lung cancer diagnosis and treatment costs from a 2012 Australian hospital-based study, lung cancer survival rates from the New South Wales Cancer Registry (2005-2009), and other-cause mortality from Australian life tables weighted by smoking status. The health utility outcomes, screening participation rates, and lung cancer rates were those observed in the NLST. Incremental cost effectiveness ratios (ICER) were calculated for a 10-year time horizon. RESULTS: The cost-effectiveness of LDCT lung screening was estimated at AU$138,000 (80% confidence interval: AU$84,700-AU$353,000)/life-year gained and AU$233,000 (80% confidence interval: AU$128,000-AU$1,110,000)/quality-adjusted life year (QALY) gained. The ICER was more favorable when LDCT screening impact on all-cause mortality was considered, even when the costs of incidental findings were also estimated in sensitivity analyses: AU$157,000/QALY gained. This can be compared to an indicative willingness-to-pay threshold in Australia of AU$30,000 to AU$50,000/QALY. CONCLUSIONS: LDCT lung screening using NLST selection and implementation criteria is unlikely to be cost-effective in Australia. Future economic evaluations should consider alternative screening eligibility criteria, intervals, nodule management, the impact and cost of new therapies, investigations of incidental findings, and incorporation of smoking cessation interventions.
引用
- Wade S, Weber M, Caruana M, et al. Estimating the Cost-Effectiveness of Lung Cancer Screening with Low-Dose Computed Tomography for High-Risk Smokers in Australia. J Thorac Oncol. 2018. PMID: 29689434. doi:10.1016/j.jtho.2018.04.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。